Skip to content
Homepage
Free · Private · Published formula

CJC-1295 and Ipamorelin Dosage Calculator: Units per Dose

Enter the total milligrams in your blended CJC-1295 and ipamorelin vial, the bacteriostatic water you add, and the dose in micrograms your clinician prescribed. You get the concentration, the volume to draw, the units on a U-100 insulin syringe, and how many doses the vial holds, plus how the draw splits between the two peptides. Arithmetic for a prescribed dose, with the formula and its limits shown.

  • Calculator
  • About 3 min
  • Standard reconstitution arithmetic (Boyer, Math for Nurses)
  • Runs in your browser, nothing is sent
  • Medical review: Medical review pending
Open the calculator

What this calculator works out

A blended vial contains two peptides in one powder, and once water is added the liquid carries both in the vial's ratio. The arithmetic treats the vial as one total and the draw as one volume; the split between the peptides is the ratio on the label, and the page shows it.

  1. 1

    Concentration after mixing

    Micrograms of combined peptide per milliliter: the vial's total milligrams divided by the water you add. A vial labeled 5 mg CJC-1295 and 5 mg ipamorelin is a 10 mg vial for this purpose; with 2 mL of water it holds 5,000 mcg/mL.

  2. 2

    Volume and syringe units

    The milliliters that contain your prescribed total micrograms, and the same volume as units on a U-100 insulin syringe (100 units is 1 mL). Every unit drawn carries both peptides in the vial's ratio, so a 1:1 vial delivers half the micrograms as each.

  3. 3

    Doses per vial

    How many full doses the vial holds at your prescription, rounded down, so you know when it runs out. Blended vials are drawn from repeatedly, so this is the number most people actually need.

How this compares with a typical online quiz

FeatureTypical free quizRegenerated.com
Formula shown with a worked exampleRarelyYes, concentration, volume, units and the peptide split
Pre-filled dose presetsCommonNone; only the dose you enter from your prescription
Handles unequal blend ratiosNoYes, with the arithmetic for a prescription written per peptide
Regulatory status stated plainlyNoYes, the FDA compounding status with each page's date and our check date
DAC and no-DAC distinction explainedRarelyYes, and why it matters for the prescription, not the arithmetic
Answers sent to a serverOftenNever; scored in your browser, counts-only events

The regulatory status of CJC-1295 and ipamorelin, with dates

Neither peptide is FDA-approved for any use. CJC-1295 is a modified fragment of growth hormone-releasing hormone; ipamorelin is a synthetic growth hormone secretagogue that acts on the ghrelin receptor. Both have been studied in small human trials (Teichman and colleagues reported sustained growth hormone and IGF-1 rises with CJC-1295 in healthy adults in 2006; Raun and colleagues characterized ipamorelin in 1998), but neither has a completed approval program, an approved indication or an approved dose.

On September 29, 2023, the FDA placed CJC-1295 in category 2 of its interim list of bulk drug substances nominated for compounding under section 503A, the category for substances it judges to raise significant safety risks, citing immunogenicity and reports of increased heart rate and a systemic vasodilatory reaction. Ipamorelin acetate was placed in category 2 of the parallel 503B list the same day, citing immunogenicity from aggregation and impurities, and serious adverse events including death with intravenous administration. Both 503A nominations were then withdrawn by the nominators. The FDA's 503A category list updated September 27, 2024 removed CJC-1295 and ipamorelin acetate from category 2 on exactly that ground, and the agency's safety-risk page, current as of April 22, 2026, still lists both among the withdrawn nominations with their safety concerns set out. We checked both on October 8, 2026. A withdrawn nomination is a decision by whoever nominated the substance, not an FDA finding that the substance is safe, and it is not permission to compound: section 503A lets a pharmacy compound from a bulk substance only if that substance has a USP or NF monograph, is a component of an FDA-approved drug product, or appears on the 503A bulks list, and neither peptide meets any of the three. The agency's Pharmacy Compounding Advisory Committee reviewed ipamorelin on October 29, 2024 and the CJC-1295 group on December 4, 2024, and in both briefings the FDA proposed that the substances not be added to the 503A bulks list; as of October 8, 2026 neither had been added. Ipamorelin acetate is also still in 503B category 2 on that same safety-risk page, added September 29, 2023, which puts an outsourcing facility that compounds it outside the FDA's interim policy; CJC-1295 is not in 503B category 2 on that page. Where a clinician prescribes a blend, that prescription is off-label in the fullest sense: an unapproved compound for an unapproved use. This calculator takes only that prescribed dose and never suggests one.

How a blended vial is dosed, and how the split works

A blended vial is usually labeled with both components, for example 5 mg CJC-1295 and 5 mg ipamorelin, or 2 mg and 2 mg. The powder is one mixture, so after reconstitution every milliliter carries both peptides in the label ratio, and every unit you draw does the same. The calculator uses a single-compound formula on the total: enter the two label figures added together as the vial strength, and enter the prescribed total micrograms as the dose. For a 1:1 vial, the micrograms of each peptide in the draw are half the total. For a 10 mg vial (5 mg plus 5 mg) with 2 mL of water, the concentration is 5,000 mcg/mL; a prescribed 300 mcg of the blend is 0.06 mL, 6 units, and that draw carries 150 mcg of CJC-1295 and 150 mcg of ipamorelin.

Prescriptions are sometimes written per peptide rather than as a total, for example 100 mcg of each. For a 1:1 vial, enter the sum (200 mcg). For an unequal vial, say 2 mg CJC-1295 with 6 mg ipamorelin (8 mg total, ratio 1:3), convert the prescribed amount of one peptide to a total: the total micrograms equal the prescribed micrograms of that peptide times the vial's total milligrams divided by that peptide's milligrams. A prescription of 100 mcg of CJC-1295 from that vial is 100 times 8 divided by 2, which is 400 mcg of blend, carrying 100 mcg of CJC-1295 and 300 mcg of ipamorelin. If a prescription names amounts of both that do not match the vial's ratio, the vial cannot deliver it, and that is a question for the prescriber or pharmacy, not for the calculator.

CJC-1295 with DAC and without: why it matters for the prescription

Two different molecules share the name. CJC-1295 with DAC (drug affinity complex) binds to albumin in the blood and has a half-life measured in days, which is why the 2006 trial saw growth hormone and IGF-1 elevated for a week or more after a single injection. CJC-1295 without DAC, also called modified GRF (1-29), has a half-life of roughly half an hour. Most blended vials with ipamorelin use the no-DAC form, because the intent is a brief, pulsed stimulus at the time of injection, but the vial label decides, and the two are not interchangeable in frequency or amount.

The arithmetic on this page is identical for both: milligrams, water and micrograms. What differs is the prescription itself, including how often it is given, and the monitoring. Sustained IGF-1 elevation is the concern that follows the DAC form; the older peptides in this class, GHRP-2 and GHRP-6, raise ACTH and cortisol, while ipamorelin was selected in the Raun 1998 study precisely because it did not, and none of them changed prolactin. Impaired glucose tolerance, fluid retention and joint discomfort are the effects that follow sustained growth hormone and IGF-1 elevation. If your vial says DAC and your prescription assumes daily use, or the reverse, stop and ask the prescriber before drawing anything.

Water volume, powder displacement and syringe choice

Adding more water dilutes the vial without changing its contents, so the same dose becomes a larger, easier draw. A 10 mg blended vial with 1 mL of water holds 10,000 mcg/mL, and a 300 mcg dose is 3 units, which is hard to read on any syringe. With 3 mL of water the same dose is 9 units. The water volume should be whatever your pharmacy or clinician specified for that vial; if the draw is too small to measure, ask them about a larger volume rather than changing it on your own, because it alters every draw from that vial.

The calculator assumes the final volume equals the water added, ignoring the small volume the powder occupies. For vials of a few milligrams that error is around a percent; it grows with larger vials, and a concentration printed by a pharmacy takes precedence over this arithmetic. On a U-100 insulin syringe one unit is 0.01 mL whatever is in the syringe. Use the smallest syringe that holds the draw, 0.3 mL (30 units) where possible, expel air before reading, and treat any draw under about 5 units or any fraction you cannot read as a question for the pharmacist, not a number to inject.

Methodology and sources

The calculator implements the standard dimensional analysis for reconstituting a lyophilized vial, as taught in nursing dosage calculation texts such as Boyer's Math for Nurses and reflected in USP General Chapter 797 practice on diluent volumes. Concentration in micrograms per milliliter equals the vial's milligrams times 1,000 divided by the milliliters of diluent added; volume per dose equals the prescribed micrograms divided by that concentration; units on a U-100 syringe equal milliliters times 100; doses per vial equal the vial's micrograms divided by the dose, rounded down. For a blended vial the formula is applied to the total milligrams of both peptides, and the draw carries them in the label ratio. Its limits: it ignores powder displacement, assumes a U-100 syringe, cannot check that a per-peptide prescription matches the vial's ratio, and has no knowledge of what dose is appropriate; it reports whatever micrograms you enter.

How this is calculated: a 5 mg vial reconstituted with 2 mL of bacteriostatic water holds 5,000 mcg divided by 2 mL, which is 2,500 mcg/mL. A prescribed dose of 250 mcg is 250 divided by 2,500, which is 0.1 mL, and 0.1 mL times 100 is 10 units on a U-100 syringe; the vial holds 5,000 divided by 250, which is 20 such doses. For a blended vial the same steps apply to the total: 5 mg CJC-1295 plus 5 mg ipamorelin is 10 mg, with 2 mL of water that is 5,000 mcg/mL, a 300 mcg dose is 0.06 mL or 6 units, the vial holds 33 such doses, and each draw carries 150 mcg of each peptide.

There are no clinical bands, because a syringe draw is not a result to interpret. The bands on this page read the units figure for one purpose: whether the draw is large enough to measure accurately on an insulin syringe, and what to do when it is not. The regulatory facts in the sections above come from the FDA's safety-risk page for bulk drug substances, current as of April 22, 2026, its 503A category lists updated September 27, 2024 and May 14, 2026, and its records for the Pharmacy Compounding Advisory Committee meetings of October 29 and December 4, 2024, each checked on October 8, 2026, and the only dose this calculator uses is the one your clinician prescribed.

Medical review: Medical review pending. Last updated .

References

  1. Boyer MJ. Math for Nurses: A Pocket Guide to Dosage Calculation and Drug Preparation. 9th ed. Philadelphia, PA: Wolters Kluwer; 2016.
  2. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of April 22, 2026; checked October 8, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  3. US Food and Drug Administration. December 4, 2024: Meeting of the Pharmacy Compounding Advisory Committee (CJC-1295 and related substances), and Bulk drug substances nominated for use in compounding under section 503A, category list updated September 27, 2024 and May 14, 2026. Checked October 8, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/december-4-2024-meeting-pharmacy-compounding-advisory-committee-12042024 and https://www.fda.gov/media/94155/download
  4. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
  5. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552

CJC-1295 and Ipamorelin Dosage Calculator: Units per Dose FAQ

No. It converts a dose your clinician already prescribed into milliliters and syringe units for the vial in front of you. It never suggests a dose, and the only dose it uses is the one you enter from your prescription. Neither peptide has an approved dose for any use, so there is no label figure to fall back on.

Take a vial labeled 5 mg CJC-1295 and 5 mg ipamorelin, reconstituted with 2 mL of water. Enter 10 as the vial strength: the concentration is 5,000 mcg/mL. A prescribed 300 mcg of the blend is 0.06 mL, which is 6 units on a U-100 syringe, and the vial holds 33 such doses. Because the vial is 1:1, that 6-unit draw carries 150 mcg of CJC-1295 and 150 mcg of ipamorelin. With the same vial and 3 mL of water, the same 300 mcg is 9 units; the split is unchanged.

For a 1:1 vial, enter the sum, 200 mcg. For an unequal vial, convert the amount of one peptide to a total: prescribed micrograms of that peptide times the vial's total milligrams divided by that peptide's milligrams. From a vial of 2 mg CJC-1295 and 6 mg ipamorelin, 100 mcg of CJC-1295 is 100 times 8 divided by 2, which is 400 mcg of blend, carrying 300 mcg of ipamorelin. If the prescription's two amounts do not fit the vial's ratio, the vial cannot deliver it; ask the prescriber.

Neither is FDA-approved for any use, and neither is a substance a US pharmacy may compound from bulk. In September 2023 the FDA placed CJC-1295 in 503A category 2 and ipamorelin acetate in 503B category 2 for significant safety risks. Both 503A nominations were later withdrawn by the nominators, which the FDA's 503A category list recorded on September 27, 2024 and its safety-risk page, current as of April 22, 2026, still shows; we checked both on October 8, 2026. A withdrawn nomination is a decision by whoever nominated the substance, not an FDA finding that the substance is safe, and it is not permission to compound. Section 503A lets a pharmacy compound from a bulk substance only if that substance has a USP or NF monograph, is a component of an FDA-approved drug product, or appears on the 503A bulks list, and neither peptide qualifies. That same page, current as of April 22, 2026 and read by us on October 8, 2026, also showed ipamorelin acetate in 503B category 2. Where a clinician prescribes a blend, that is a clinician-directed, off-label decision made on their responsibility; a listing on Regenerated.com is not a statement about legality or safety.

No. The water sets the concentration, so the same dose becomes a different number of units; the micrograms are unchanged. Use the volume your pharmacy or clinician specified. If the resulting draw is too small to read, ask them whether a larger volume is appropriate for your vial rather than changing it yourself.

Yes. Your answers and the numbers you enter are scored in your browser and are never sent to us. They stay in this browser tab so you can return to your result, and closing the tab clears them. The only thing the page sends us is a counts-only event: which test was started or completed, the result band and the headline number, with no answers, no entered values and no account. There is nothing to sign up for.

Find clinics that prescribe peptides with oversight

Browse US clinics offering peptide therapy. Look for physician oversight, baseline and repeat labs, a plain statement that these peptides are unapproved and what that means, a pharmacy that labels the vial with its concentration, and risks explained before prescribing. A listing on Regenerated.com is not an endorsement.

Browse peptide therapy clinics

A listing is not a treatment endorsement. Read each clinic's published checks and talk to your clinician before starting any treatment.

Important: This calculator is arithmetic on a dose your clinician prescribed. It is not a recommendation to use CJC-1295, ipamorelin or any peptide, not a dose for any purpose, and not medical advice. Neither peptide is FDA-approved, the FDA has published safety concerns about compounding both, and neither was on the 503A bulks list when we checked on October 8, 2026, so neither is a substance a US pharmacy may compound from bulk; any use is off-label and clinician-directed. Confirm every draw with the clinician or pharmacist who dispensed the vial. If your symptoms are severe or sudden, seek urgent medical care.